Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488719 | 0.95 | BRD4 (0.60) | BRD4KDM4ENPC1RAB9AMAPT | |
| SCHEMBL4480130 | 0.95 | BRD4 (0.58) | BRD4KDM4ENPC1RAB9AMAPT | |
| SCHEMBL4477848 | 0.84 | BRD4 (0.41) | BRD4KDM4ENPC1RAB9AMAPT | |
| SCHEMBL4493667 | 0.82 | SYK (0.46) | BRD4KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL4495043 | 0.82 | SLC16A3 (0.46) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL4487682 | 0.82 | ALDH1A1 (0.49) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL4487199 | 0.81 | BRD4 (0.45) | BRD4KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL4482160 | 0.81 | AURKA (0.46) | BRD4KDM4EMAPT | |
| SCHEMBL4478082 | 0.81 | MEN1 (0.52) | BRD4KDM4ENPC1RAB9AMAPT | |
| SCHEMBL4481447 | 0.81 | FERMT2 (0.45) | BRD4KDM4ENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | claimed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | claimed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | disclosed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106058-A1 | Chemical compounds | YARS1, DAPK3, NEK3 | BRD4 336/4885KDM4E 1641/4885NPC1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.